Eidos Therapeutics Initiates Attribute-CM, a Phase 3 Study of AG10 in ATTR-CM with Registrational 12-month Endpoint

ATTRibute-CM study design, which incorporates feedback from the FDA, has the potential to accelerate registration with a 12-month primary endpoint of change in 6-minute walk distance (6MWD), followed by a 30-month endpoint of mortality and cardiovascular-related hospitalizations Trial sites activated in global Phase 3 study (ATTRibute-CM) of AG10 in patients with transthyretin amyloidosis cardiomyopathy Eidos to […]

Phoenix Tissue Repair Doses First Patient in Phase 1/2 Clinical Trial of PTR-01 (BBP-589) for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

BOSTON, Feb. 22, 2019 /PRNewswire/ — Phoenix Tissue Repair, Inc., a biotechnology company focused on developing transformational disease-modifying treatments for dystrophic epidermolysis bullosa (DEB), today announced that the first patient has been dosed in the Phase 1/2, first in-human trial of PTR-01 (BridgeBio Pharma designation BBP-589), a protein replacement therapy for recessive DEB (RDEB). DEB and RDEB are […]